Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private

Anebulo Pharmaceuticals, Inc.

Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).
First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.
Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.
Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.
Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.